06:01 AM EDT, 07/28/2025 (MT Newswires) -- GSK (GSK) has signed agreements with Hengrui Pharma to develop up to 12 medicines across respiratory, immunology and inflammation, and oncology, Hengrui said Sunday.

GSK will pay $500 million in upfront fees across the deals.

Hengrui said the potential total value of future success-based development, regulatory and commercial milestone payments to the company is about $12 billion, if all programs are optioned and all milestones are met.

Hengrui will also be eligible to receive tiered royalties on global product net sales, it said.